Propanc to Present at Rodman & Renshaw 18th Annual Global Investment Conference
Latest Scientific Research and Preclinical Data for the Company's Lead Product, PRP, as a New Approach to Eradicate Cancer Stem Cells by James Nathanielsz, CEO and Executive Chairman
MELBOURNE, AUSTRALIA -- (Marketwired) -- 08/03/16 -- Propanc Health Group Corporation (OTCQB: PPCH) ("Propanc" or "the Company"), an emerging healthcare company focusing on development of new and proprietary treatments for cancer patients suffering from solid tumors such as pancreatic, ovarian and colorectal cancers, today announced the Company will present at Rodman and Renshaw's 18th Annual Global Investment Conference, at the New York Palace Hotel, New York City, on Monday, September 12th, 2016, at 5:30pm, Eastern Daylight Time.
The presentation will focus on the latest research undertaken by the Company's for its lead product, PRP, as a method to treat and prevent metastatic cancer. PRP's unique patented approach suppresses metastasis and tumor relapse, complementing conventional therapies and is safe at specified dosages with minimal toxicity.
"We are waging a fight against cancer, but while conventional therapies kill cancer cells that replicate, deep inside are a smaller number of cells, known as cancer stem cells, that resist attack," said James Nathanielsz, Propanc's Chief Executive Officer. "To achieve a total victory over cancer, we need to target and eradicate cancer stem cells. Our lead product, PRP, is a new therapeutic approach consisting of two pancreatic proenzymes which stops the cancer stem cell machinery by turning them back into normal cells. I look forward to presenting our latest scientific data, as well as outlining our progress towards first-in-man studies in 2017."
Dr Julian Kenyon, Propanc's Chief Scientific Officer added, "It's a new frontier in cancer therapy and PRP is helping lead the way by turning off and curtailing the population of cancer stem cells whilst leaving healthy cells unharmed. PRP offers new hope for clinicians and their patients to greatly improve survival. It has the potential to transform cancer care. I am pleased to present our data to the broader investment community at such a reputable conference."
The Company aims to fast track the development of proenzyme related oncology products into clinical trials initially for pancreatic and ovarian cancers, followed by colorectal cancer. According to Global Analyst Reports, the combined world market for pancreatic, ovarian and colorectal cancers are expected to reach over $12 billion by 2020.
About Propanc:
Propanc is developing new cancer treatments for patients suffering from pancreatic, ovarian and colorectal cancers. We have developed a formulation of anti-cancer compounds, which exert a number of effects designed to control or prevent tumors from recurring and spreading throughout the body. Our products involve or employ pancreatic proenzymes, which are inactive precursors of enzymes.
In the near term, we intend to target patients with limited remaining therapeutic options for the treatment of solid tumors. In future, we intend to develop our lead product to treat (i) early stage cancer and (ii) pre-cancerous diseases and (iii) as a preventative measure for patients at risk of developing cancer based on genetic screening. For more information, visit: www.propanc.com.
Forward-Looking Statements:
All statements other than statements of historical fact contained herein are "forward-looking statements" for purposes of federal and state securities laws. Forward-looking statements may include the words "may," "will," "estimate," "intend," "continue," "believe," "expect," "plan" or "anticipate" and other similar words. Although we believe that the expectations reflected in our forward-looking statements are reasonable, actual results could differ materially from those projected or assumed. Our future financial condition and results of operations, as well as any forward-looking statements, are subject to change and to inherent risks and uncertainties including those regarding our earnings, revenues and financial condition, our ability to implement our plans, strategies and objectives for future operations, our ability to execute on proposed new products, services or development thereof, our ability to establish and maintain the proprietary nature of our technology through the patent process, our ability to license from others patents and patent applications, if necessary, to develop certain products, our ability to implement our long range business plan for various applications of our technology, our ability to enter into agreements with any necessary manufacturing, marketing and/or distribution partners for purposes of commercialization, the results of our clinical research and development, competition in the industry in which we operate, overall market conditions, and any statements or assumptions underlying any of the foregoing. Other risks, uncertainties and factors that could cause actual results to differ materially from those projected may be described from time to time in reports we file with the Securities and Exchange Commission, including our reports on Forms 10-K, 10-Q and 8-K. We do not intend, and undertake no obligation, to update any forward-looking statement contained herein, except as required by law.
This is not a solicitation to buy or sell securities and does not purport to be an analysis of the company's financial position.
Image Available: http://www.marketwire.com/library/MwGo/2016/8/3/11G109172/Images/ctr_prp_image-db3ed2f60ae8a68d9266c5a43bd3f867.jpg
Contact:
Stanley Wunderlich
Consulting for Strategic Growth 1 Ltd
CEO
800-625-2236 ext. 7770
swunderlich@cfsg1.com
880 Third Ave (53rd Street)
6th Floor, New York, NY, 10022
www.cfsg1.com
Source: Propanc Health Group Corporation
Released August 3, 2016